Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902

Kubota, Keiichi; Tamura, Tomohide; Fukuoka, Masahiro; Furuse, Kiyoyuki; Ikegami, H; Ariyoshi, Y; Kurita, Yuichi; Saijo, Nagahiro

doi:10.1023/a:1008328207137

Cited by 18 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six multi-institutional trials met the criteria and were analyzed in this study: JCOG8902, 9201, 9306, 9405, 9504 and 9601. [8][9][10][11][12][13] 10) One point five grays twice daily, 5 days per week was delivered on weeks 1 and 2, 5 and 6, and 9 for a total dose of 66-72 Gy, alternating with cisplatin plus vindesine repeated every 4 weeks beginning in week 3. Between January 1994 and December 1995, 41 patients were entered.…”

Section: Methodsmentioning

confidence: 99%

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

Ohe¹,

Ishizuka

Tamura

et al. 2003

Cancer Science

View full text Add to dashboard Cite

To clarify the long-term survival data and factors that are correlated with survival outcome of unresectable locally advanced non-small cell lung cancer (NSCLC) following chemoradiotherapy, we analyzed patients who entered the Japan Clinical Oncology Group (JCOG) clinical trials for unresectable locally advanced NSCLC. Between October 1989 and August 1997, 240 patients (male 207, female 33; PS (performance status) 0 58, PS 1 172, PS 2 9, unknown 1; stage IIB 2, IIIA 62, IIIB 175, unknown 1) entered the 6 trials. All patients received chemotherapy and radiotherapy. The associations between survival outcome and treatment-related factors were analyzed using Cox regression analysis. Median survival times and 5-year survival rates in the trials were 11.9-19.7 months and 0-17.6%, respectively. Median survival time was 16.1 months and the 5-and 7-year survival rates of all 240 patients were 14.4% and 12.0%, respectively. No deaths were observed 7 years after initiation of the treatment or later. For stage IIIA and IIIB patients, the 5-year survival rates were 16.3% and 13.4%, respectively. Node status and age were significantly associated with survival, but no factors of the treatment were associated with survival of patients with unresectable locally advanced NSCLC. The present retrospective analysis showed that approximately 12% of patients with unresectable locally advanced NSCLC could be cured by various chemoradiotherapy regimens. (Cancer Sci 2003; 94: 729-734) or many years, thoracic radiotherapy had been regarded as the standard treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC).1, 2) However, the meta-analysis of 1780 cases in 11 randomized trials showed that cisplatin-containing chemoradiotherapy is significantly superior to radiotherapy alone in terms of survival.3) On the other hand, Kubota et al. reported that the addition of radiotherapy to chemotherapy for locally advanced NSCLC significantly improved the 2-and 3-year survival rates compared to chemotherapy alone.4) Thus, the combination of cisplatin-containing chemotherapy with thoracic radiotherapy has been considered as the standard treatment for patients with unresectable locally advanced NSCLC. However, only a few reports on the longterm follow-up of chemoradiotherapy are available.5) The longterm survival, especially that longer than 5 years, of patients with unresectable locally advanced NSCLC who received chemoradiotherapy is still unclear.Recent reports suggest that concurrent chemoradiotherapy provides better survival for patients with unresectable locally advanced NSCLC than chemotherapy followed by radiotherapy.6, 7) However, the treatment has not been satisfactory in terms of patient survival due to the high rates of both distant and local recurrence. The most effective combination of chemotherapy and radiotherapy is still unknown. The Japan Clinical Oncology Group (JCOG) has been conducting several trials for patients with unresectable locally advanced NSCLC to improve survival. [8][9][10][11][12]...

show abstract

Section: Methodsmentioning

confidence: 99%

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

Ohe¹,

Ishizuka

Tamura

et al. 2003

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Given that all our patients were not surgical candidates, lung RFA seems to provide survival benefit. In patients with unresectable lung cancer, the median survival time has been reported to be 14.8 months after concurrent chemotherapy and radiotherapy [29] and 11.4 months after radiotherapy [30].…”

Section: Complications Of Lung Radiofrequency Ablationmentioning

confidence: 99%

Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences

Kashima

Yamakado²,

Takaki³

et al. 2011

American Journal of Roentgenology

195

131

View full text Add to dashboard Cite

show abstract

“…Use of cisplatin/vindesine with RT produced Grade 3 or greater leukopenia in 93%. 11 Use of concurrent carboplatin and paclitaxel with RT produced neutropenia in 12%. 13 The neutropenia in this study was decreased from what was initially expected, which may be attributable to the low cisplatin dose schedule used.…”

Section: Discussionmentioning

confidence: 99%

Five-Year Results of a Phase II Trial of Hyperfractionated Radiotherapy and Concurrent Daily Cisplatin Chemotherapy for Stage III Non-Small-Cell Lung Cancer

Keene

Harman²,

Knauf³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this study was to evaluate the 5-year results for a phase II trial of hyperfractionated radiotherapy (RT) and concurrent daily cisplatin chemotherapy. Between August 1994 and December 1999, 63 patients with stage IIIA and stage IIIB non-small-cell lung cancer were treated with RT to a dose of 69.6 Gy at 1.2 Gy twice daily with daily cisplatin at 6 mg/m. Thirty-seven patients elected to receive consolidation carboplatin and paclitaxel chemotherapy. Recurrence and survival outcomes were evaluated by Kaplan-Meier analysis. Acute and late side effects were scored by the Radiation Therapy Oncology Group (RTOG) grading system. Radiographic complete or partial tumor response was achieved in 34 of 63 (54%) of cases. Median absolute survival was 20.1 months. Median time to local recurrence and distant metastases were 10.6 and 8.6 months, respectively. Overall survival rates were 57%, 35%, and 23% at 1, 3, and 5 years, respectively. Survival was significantly greater for patients receiving consolidation chemotherapy (50% versus 20% at 3 years). Only 5 patients (7%) experienced Grade 3 or 4 esophagitis. There were 16 cases of Grade 1 or 2 pneumonitis; steroid therapy resolved symptoms in 9 patients. This regimen of hyperfractionated RT and chemotherapy achieved significant response, and 5-year survival rates with acceptable toxicity.

show abstract

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902

Abstract: Concurrent chemotherapy and radiotherapy has the potential to provide long-term survival with acceptable toxicities.

Cited by 18 publications

References 18 publications

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences

Five-Year Results of a Phase II Trial of Hyperfractionated Radiotherapy and Concurrent Daily Cisplatin Chemotherapy for Stage III Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About